Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma

Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma

Theproteasome inhibitor bortezomib (Velcade) has demonstrated clinical activity in patients with multiple myeloma (MM). We report the activity of borte-zomib plus dexamethasone in 60patients with relapsed and refractory myeloma. The patients had a median age of 65 years (range, 38—79 years). The med...

Full description

Bibliographic Details
Main Authors: S. S. Bessmeltsev, L. V. Stelmashenko, E. I. Podoltseva, E. V. Kariagina, G. N. Salogub, А. S. Nisamutdinova, L. M. Matuhina, K. M. Abdulkadyrov
Format: Article
Language:Russian
Published: ABV-press 2022-11-01
Series:Онкогематология
Subjects:
bortezomib (velcade)
multiple myeloma
complete remission
overall response
neuropathy
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/676

Internet

https://oncohematology.abvpress.ru/ongm/article/view/676

Similar Items